K2M Group Holdings, Inc. to Present at Two Investor Conferences in September
September 01 2016 - 10:00AM
K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a
global medical device company focused on designing, developing and
commercializing innovative and proprietary complex spine and
minimally invasive spine technologies and techniques, today
announced management will present at the following investor
conferences in September:
The 2016 Wells Fargo Healthcare
Conference at the Westin Boston Waterfront in Boston,
Massachusetts
- Management will present on Thursday, September 8 at 2:20 p.m.
Eastern Time
The Morgan Stanley Global Healthcare
Conference at the Grand Hyatt in New York, New
York
- Management will present on Monday, September 12 at 1:05 p.m.
Eastern Time
Live audio webcasts of the presentations will be provided under
the 'Events & Presentations' section of the Company's investor
relations website at http://investors.K2M.com/. It is recommended
that listeners log on 15 minutes early in order to register and
download any necessary software. An archive of the webcast will be
available for replay following the conference.
About K2M
K2M Group Holdings, Inc. is a global medical device company
focused on designing, developing and commercializing innovative
complex spine and minimally invasive spine technologies and
techniques used by spine surgeons to treat some of the most
difficult and challenging spinal pathologies. K2M has leveraged
these core competencies to bring to market an increasing number of
products for patients suffering from degenerative spinal
conditions. These technologies and techniques, in combination with
a robust product pipeline, enable the Company to favorably compete
in the global spinal surgery market. Additional information is
available online at www.K2M.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that reflect current views with
respect to, among other things, operations and financial
performance. Forward-looking statements include all statements that
are not historical facts such as our statements about our expected
financial results and guidance and our expectations for future
business prospects, including with respect to our international
distribution partners in Australia and Japan. In some cases, you
can identify these forward-looking statements by the use of words
such as “outlook,” “guidance,” “believes,” “expects,” “potential,”
“continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,”
“intends,” “plans,” “estimates,” “anticipates” or the negative
version of these words or other comparable words. Such
forward-looking statements are subject to various risks and
uncertainties including, among other things: our ability to achieve
or sustain profitability; our ability to successfully demonstrate
the merits of our technologies and techniques; pricing pressure
from our competitors, hospitals and changes in third-party coverage
and reimbursement; competition and our ability to develop and
commercialize new products; the greater resources available to some
of our competitors; aggregation of hospital purchasing from
collaboration and consolidation; hospitals and other healthcare
providers may be unable to obtain adequate coverage and
reimbursement for procedures performed using our products; the
safety and efficacy of our products is not yet supported by
long-term clinical data; our dependence on a limited number of
third-party suppliers; our ability to maintain and expand our
network of direct sales employees, independent sales agencies and
international distributors and their level of sales or distribution
activity with respect our products; the proliferation of
physician-owned distributorships; concentration of sales from a
limited number of spinal systems or products that incorporate these
technologies; loss of the services of key members of our senior
management, consultants or personnel; ability to enhance our
product offerings through our research and development efforts;
failure to properly manage our anticipated growth; acquisitions of
or investments in new or complementary businesses, products or
technologies; ability to train surgeons on the safe and appropriate
use of our products; requirements to maintain high levels of
inventory; impairment of our goodwill or intangible assets;
disruptions in our information technology systems; any disruption
or delays in operations at our facilities, including our new
headquarters facility; our ability to ship a sufficient number of
our products to meet demand; ability to strengthen our brand;
fluctuations in insurance cost and availability; extensive
governmental regulation including by the FDA; in the United States
and foreign jurisdictions; failure to obtain or maintain regulatory
approvals and FDA clearances; requirements for new 510(k)
clearances, premarket approvals or new or amended CE Certificates
of Conformity; medical device reporting regulations in the United
States and foreign jurisdictions; voluntary corrective actions by
us or our distribution or other business partners or agency
enforcement actions; a recall of our products; withdrawal or
restrictions on our products or the discovery of serious safety
issues with our products; possible enforcement action if we engage
in improper marketing or promotion of our products; the misuse or
off-label use of our products; delays or failures in any future
clinical trials; our reliance on the performance of third parties
who assist us in clinical trials and pre-clinical development; the
results of clinical trials; procurement and use of allograft bone
tissue; environmental laws and regulations; compliance by us or our
sales representatives with FDA regulations or fraud and abuse laws;
U.S. legislative or regulatory healthcare reforms; medical device
tax provisions in the healthcare reform laws; our need to generate
significant sales to become profitable; potential fluctuations in
sales volumes and our results of operations over the course of the
year; uncertainty in our future capital needs; failure to comply
with restrictions in our revolving credit facility; continuing
worldwide economic instability; our inability to protect our
intellectual property rights; our reliance on patent rights that we
either license from others or have obtained through assignments;
our patent litigation; the outcome of potential claims that we, our
employees, our independent sales agencies or our distributors have
wrongfully used or disclosed alleged trade secrets or are in breach
of non-competition or non-solicitation agreements with our
competitors; potential product liability lawsuits; operating risks
relating to our international operations; foreign currency
fluctuations; our ability to comply with the Foreign Corrupt
Practices Act and similar laws associated with our activities
outside the United States; possible conflicts of interest with our
large shareholders; increased costs and additional regulations and
requirements as a result of becoming a public company; our ability
to implement and maintain effective internal control over financial
reporting in the future; volatility in our common stock; our
current plans not to pay dividends; potential dilution due to our
issuance of common stock under our incentive plans, for
acquisitions or otherwise; the amount of common stock held by our
pre-IPO owners; the impact of anti-takeover provisions in our
organizational documents and under Delaware law; our status as an
emerging growth company, our ability to use our net operating loss
carryforwards; the potential impact of any future acquisitions,
mergers, dispositions, joint ventures, investments or other
strategic transactions we may make; and other risks and
uncertainties, including those described under the section entitled
“Risk Factors” in our most recent Annual Report on Form 10-K filed
with the SEC, as such factors may be updated from time to time in
our periodic filings with the SEC, which are accessible on the
SEC’s website at www.sec.gov. Accordingly, there are or will be
important factors that could cause actual outcomes or results to
differ materially from those indicated in these statements. These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in this release and our filings with the SEC.
We operate in a very competitive and challenging environment.
New risks and uncertainties emerge from time to time, and it is not
possible for us to predict all risks and uncertainties that could
have an impact on the forward-looking statements contained in this
release. We cannot assure you that the results, events and
circumstances reflected in the forward-looking statements will be
achieved or occur, and actual results, events or circumstances
could differ materially from those described in the forward-looking
statements.
The forward-looking statements made in this press release relate
only to events as of the date on which the statements are made. We
undertake no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as required by law. We may
not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements and you should not
place undue reliance on our forward-looking statements.
Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.
Mike Piccinino, CFA, 443-213-0500
K2M@westwicke.com
K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
Historical Stock Chart
From Mar 2024 to Apr 2024
K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
Historical Stock Chart
From Apr 2023 to Apr 2024